Shots:

• The P-III STRATA2016 trial evaluates the efficacy & safety of StrataGraft treatment vs autograft in 71 patients aged >18 yrs. with deep partial-thickness thermal burns across 12 burn centers in the US. The trial was supported by BARDA
• The study met its both co-primary efficacy EPs i.e 96% did not require autografting & 83.1% of patients achieved durable wound closure without autografting @3mos.- 86% of patients achieved durable wound closure of the autograft control sites
• The 2EPs also showed favorable outcomes & reduction in the use of autograft. The cosmesis at StrataGraft & autograft treatment sites were clinically similar @12mos. The results are published in Burns

  Ref: PR Newswire | Image: CNBC